PR Hamlet Biopharma_ENG_261110.pdf
The bladder cancer drug candidate Alpha1H is featured in a new scientific review published in the journal Biomedicines. Independent researchers at the internationally renowned Tongji University in Shanghai highlight Alpha1H’s clinical results and three biological effects identified in previous studies.
The authors describe how Alpha1H affects bladder cancer tumors through direct effects on cancer cells, activation of the immune response, and changes in tumor metabolism.
Clinical studies have demonstrated dose-dependent tumor reduction and good tolerability. The researchers also highlight immune responses resembling those previously reported following BCG treatment, as well as new findings published in 2026 on Alpha1H’s effects on bladder cancer, including metabolic signaling pathways in bladder cancer tumors.
The publication provides a consolidated overview of important findings from the clinical development program and brings further independent international scientific attention to the research conducted by scientists affiliated with Lund University and the drug development collaboration with Linnane Pharma.
Alpha1H is currently in Phase III clinical development, with patient treatment underway, and has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
Publication: Wei Y. and Hao H. Natural Products Targeting Regulated Cell Death in Bladder Cancer: Pathway Mechanisms, Crosstalk and Intravesical Translation. Biomedicines, November 4, 2026. https://doi.org/10.3390/biomedicines14112540
For further information, please contact
Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46 709 42 65 49,
catharina.svanborg@hamletpharma.com
Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10,